Search filters

FoRx Therapeutics AG raises EUR 10M Seed-Financing round

FoRx Therapeutics AG, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round led by M...

RLF sells its subsidiary to Sonnet BioTherapeutics Holdings, Inc

RELIEF THERAPEUTICS Holding SA (SIX:RLF; "Relief Holding") announces today the closing of the binding Share Exchange Agreement for the acquisition by Sonnet BioTherapeutics, Inc. ("Sonnet"), now a subsidiary of Sonnet...

NBE-Therapeutics closes USD 22M Series C financing round

NBE-Therapeutics AG closed a USD 22M Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders. The funds will enable NBE to...

Oviva raises USD 21M to roll out digital diabetes treatment in Europe

Oviva raises USD 21M to roll out digital diabetes treatment in Europe.

The round was led by Swiss healthtech investor MTIP, joined by Earlybird as new investors. Existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures...

Resistell Closes Series A Financing Round

Resistell AG has closed a milestone-based CHF 3.5M Series A Financing round led by OCCIDENT. TRUMPF Venture, Alpana Ventures, Zürcher Kantonalbank, HEMEX and seven private investors also back the start-up developing world’s...

Numab and Sunshine Guojian form partnership

3SBio Inc.’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”) and Numab have formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific...

ARTIDIS announces CHF 8.8M seed financing round

ARTIDIS AG ("ARTIDIS"), a privately held healthtech company, announced the successful closure of a CHF 8.8M seed financing in two rounds, securing early clinical validation and the next development phase towards market entry in...

Kuros Biosciences AG completes rights offering and share placement

Kuros Biosciences (SIX: KURN) completes a rights offering and share placement in which a total of 6,405,022 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00...

ImmunOs Therapeutics AG raises CHF 15M in Series A Financing

ImmunOs Therapeutics AG, a Swiss biotechnology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A financing of CHF 15 million....

EraCal Therapeutics AG Closes Seed Financing Round

EraCal Therapeutics AG, established as a spin-off from the University of Zurich and Harvard University, completes an oversubscribed seed financing round. Investors included Bernina BioInvest, Redalpine, the UZH Life Sciences Fund...

You are currently offline. Some pages or content may fail to load.